Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.
Our Work

Latham & Watkins Advises CalciMedica in Secured Growth Financing

March 5, 2025
Firm represented the leading inflammation immune biotech company in the transaction.

CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has announced that the Company has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to US$32.5 million. Proceeds from the facility are intended to support the continued development of the Company's product pipeline.

Latham & Watkins LLP represented CalciMedica in the transaction with a transaction team led by partners Haim Zaltzman, Dan Van Fleet, and Alex Kassai, with associates Tony Noh and Zuzanna Gruca. Advice was also provided on tax matters by partner Eric Cho.

Endnotes

    Contacts

    Zaltzman, Haim

    Haim Zaltzman

    New York / San Francisco / Silicon Valley
    haim.zaltzman@lw.com
    Van Fleet, Dan

    Dan Van Fleet

    San Francisco / Silicon Valley
    dan.vanfleet@lw.com +1.415.391.0600
    Kassai, Alex

    Alex K. Kassai

    Silicon Valley / San Francisco
    alex.kassai@lw.com +1.650.470.2206